Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Pfizer Inc Stock Research

PFE

33.62USD-0.37(-1.09%)Market Closed
Watchlist

Market Summary

USD33.62-0.37
Market Closed
-1.09%

PFE Alerts

PFE Stock Price

PFE RSI Chart

PFE Valuation

Market Cap

189.8B

Price/Earnings (Trailing)

8.84

Price/Sales (Trailing)

2.44

EV/EBITDA

6.16

Price/Free Cashflow

17.8

PFE Price/Sales (Trailing)

PFE Profitability

EBT Margin

34.37%

Return on Equity

28.77%

Return on Assets

14.82%

Free Cashflow Yield

5.62%

PFE Fundamentals

PFE Revenue

Revenue (TTM)

77.9B

Revenue Y/Y

-54.1%

Revenue Q/Q

-30.35%

PFE Earnings

Earnings (TTM)

21.5B

Earnings Y/Y

-76.51%

Earnings Q/Q

-58.02%

Price Action

52 Week Range

33.4454.93
(Low)(High)

Last 7 days

-1.3%

Last 30 days

-9.2%

Last 90 days

-13.2%

Trailing 12 Months

-24.3%

PFE Financial Health

Current Ratio

1.37

PFE Investor Care

Dividend Yield

4.85%

Dividend/Share (TTM)

1.63

Shares Dilution (1Y)

0.95%

Diluted EPS (TTM)

3.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for PFE

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-31
Denton David M
sold (taxes)
-616,798
38.02
-16,223
chief financial officer & evp
2023-05-08
Gottlieb Scott
bought
38,580
38.58
1,000
-
2023-05-05
Gottlieb Scott
bought
38,425
38.425
1,000
-
2023-03-31
Pao William
sold (taxes)
-901,476
40.8
-22,095
executive vice president
2023-03-15
DAMICO JENNIFER B.
sold
-396,678
40.02
-9,912
svp & controller
2023-02-27
SAHNI PAYAL
sold (taxes)
-52,891
40.78
-1,297
executive vice president
2023-02-27
McDermott Michael
sold (taxes)
-125,643
40.78
-3,081
executive vice president
2023-02-27
DAMICO JENNIFER B.
sold (taxes)
-58,193
40.78
-1,427
svp & controller
2023-02-25
SAHNI PAYAL
acquired
204,202
22.89
8,921
executive vice president
2023-02-25
LANKLER DOUGLAS M
sold (taxes)
-1,101,740
41.75
-26,389
executive vice president

1–10 of 50

Which funds bought or sold PFE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-19
BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL
reduced
-7.91
-995,067
4,785,640
2.00%
2023-09-18
CAPE ANN SAVINGS BANK
added
4.7
-40,824
654,775
0.44%
2023-09-15
CJM Wealth Advisers, Ltd.
sold off
-100
-284,577
-
-%
2023-09-14
IMS Capital Management
added
22.05
264,254
2,980,970
1.66%
2023-09-13
CGC Financial Services, LLC
new
-
72,746
72,746
0.05%
2023-09-12
DCM Advisors, LLC
reduced
-0.06
-251,082
2,221,190
0.95%
2023-09-12
Prosperity Financial Group, Inc.
added
29.56
45,755
323,481
0.28%
2023-09-12
Prosperity Wealth Management, Inc.
added
1.93
-23,380
256,100
0.17%
2023-09-12
Farther Finance Advisors, LLC
added
14.97
21,065
648,487
0.14%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
added
180
267,467
442,877
0.13%

1–10 of 46

Latest Funds Activity

Are funds buying PFE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PFE
No. of Funds

Schedule 13G FIlings of Pfizer

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
8.94%
501,636,220
SC 13G/A
Feb 07, 2023
state street corp
5.08%
284,943,697
SC 13G/A
Feb 03, 2023
blackrock inc.
7.9%
442,868,761
SC 13G/A
Feb 14, 2022
state street corp
5.09%
285,771,591
SC 13G/A
Feb 10, 2022
vanguard group inc
8.29%
465,274,925
SC 13G/A
Feb 01, 2022
blackrock inc.
7.3%
409,985,645
SC 13G/A
Feb 12, 2021
state street corp
5.03%
279,831,373
SC 13G
Feb 10, 2021
vanguard group inc
8.06%
447,958,747
SC 13G/A
Jan 29, 2021
blackrock inc.
7.1%
396,973,512
SC 13G/A
Feb 13, 2020
state street corp
5.28%
292,628,794
SC 13G

Recent SEC filings of Pfizer

View All Filings
Date Filed Form Type Document
Sep 18, 2023
4
Insider Trading
Sep 18, 2023
4
Insider Trading
Sep 18, 2023
4
Insider Trading
Sep 13, 2023
144
Notice of Insider Sale Intent
Sep 11, 2023
SC 13D/A
13D - Major Acquisition
Sep 01, 2023
4
Insider Trading
Sep 01, 2023
4
Insider Trading
Sep 01, 2023
4
Insider Trading
Aug 16, 2023
4
Insider Trading
Aug 16, 2023
4
Insider Trading

PFE Fair Value

Loading...

Peers (Alternatives to Pfizer)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
512.5B
29.5B
3.56% 89.32%
78.88
17.36
1.53% 14.16%
423.3B
97.8B
-2.65% 0.10%
32.43
4.33
2.29% -28.92%
272.8B
58.3B
-2.13% 26.48%
17.88
4.63
2.00% -81.24%
189.8B
77.9B
-9.16% -24.26%
8.84
2.44
-23.04% -26.74%
150.1B
45.2B
-5.06% -15.06%
23.72
3.25
-4.15% 20.34%
MID-CAP
6.5B
-
1.75% 544.26%
-74.04
4.1K
-86.94% 71.24%
4.5B
4.6B
-11.49% -16.32%
-66.69
0.98
6.60% 42.04%
SMALL-CAP
1.9B
627.1M
-7.75% -1.79%
-1.34
3.1
-0.20% -204.67%
1.5B
634.0M
-11.88% -19.94%
34.62
2.37
0.62% -24.59%
832.3M
244.3M
-4.13% 4.68%
4.22
3.41
-39.50% -4.99%
830.8M
109.5M
21.79% -27.57%
-5.79
7.59
-2.66% -32.13%
480.0M
453.3M
110.37% -71.69%
-0.39
1.06
-16.04% 55.90%
479.1M
31.2M
-7.77% -52.62%
-4.55
15.37
407.54% -26.47%
269.4M
54.6M
-13.04% -44.44%
-2.97
4.93
9.39% -179.16%
-
2.2B
- -
-
-
-22.39% 63.59%

Pfizer News

MarketWatch
Pfizer Inc. stock falls Wednesday, underperforms market.
MarketWatch,
7 hours ago
The Motley Fool
Pfizer Stock: Bear vs. Bull.
The Motley Fool,
37 hours ago

Returns for PFE

Cumulative Returns on PFE

4.9%


10-Year Cumulative Returns

3.1%


7-Year Cumulative Returns

-2.3%


5-Year Cumulative Returns

-0.2%


3-Year Cumulative Returns

Risks for PFE

What is the probability of a big loss on PFE?

56.1%


Probability that Pfizer stock will be more than 20% underwater in next one year

11.5%


Probability that Pfizer stock will be more than 30% underwater in next one year.

0%


Probability that Pfizer stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PFE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Pfizer was unfortunately bought at previous high price.

Drawdowns

Financials for Pfizer

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-16.1%77,94492,952100,33099,879101,27692,43381,28868,87755,11946,08441,65132,06734,47037,87040,90540,21740,83541,03740,82553,37353,243
  S&GA Expenses3.1%14,95114,50213,67713,13612,64412,51912,70312,33812,09711,83311,59710,47411,07611,92812,72612,27412,50812,53912,61215,00315,013
EBITDA-100.0%-33,35736,17134,70833,95634,34430,969--18,23913,8198,77517,37618,47718,82725,37118,628----
EBITDA Margin-100.0%-0.36*0.36*0.35*0.34*0.37*0.38*--0.45*0.33*0.20*0.37*0.36*0.36*0.48*0.35*----
Interest Expenses6.0%1,4921,4081,4421,3831,4401,4751,4671,5491,5291,6141,6411,6381,6881,6741,5871,5891,3961,4371,3111,3851,361
Earnings Before Taxes-28.7%22,77131,94934,72933,32532,16727,66924,31121,08213,8099,8867,036-1,4318,7269,84111,3219,9543,4043,7903,59413,78513,193
EBT Margin-100.0%-0.34*0.35*0.33*0.32*0.30*0.30*0.30*0.24*0.30*0.18*0.03*0.21*0.22*0.22*------
Net Income-26.1%21,47229,05131,37229,77129,30924,96621,97919,43212,75510,6819,1597,73013,94115,49816,02616,21712,65111,47711,15323,82122,547
Net Income Margin-100.0%-0.31*0.31*0.30*0.29*0.27*0.27*0.28*0.23*0.26*0.22*0.18*0.30*0.31*0.31*------
Free Cashflow-100.0%-20,20626,03123,36228,44331,78329,86929,81421,14113,45112,15110,56612,89211,96210,516------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets12.6%220,168195,617197,000195,350195,290183,841181,000179,188169,920158,818154,000178,983178,000166,336167,594170,446156,199155,421159,000168,000164,980
  Current Assets46.5%73,34750,07851,25970,40367,46654,42059,69357,90048,81439,53335,06747,73946,42434,73832,80333,45947,07345,29049,92641,58337,303
    Cash Equivalents21.5%2,6322,1664161,2981,8242,5131,9832,0342,4181,8091,8251,6271,8452,1961,3502,8461,8372,0181,2253,6582,811
  Inventory8.1%10,3109,5418,9819,51310,4549,9799,0598,6408,9488,4938,0209,2958,5648,4237,0688,2228,2338,0297,5088,1848,074
  Net PPE2.6%17,48817,05216,27415,44115,24415,10914,88214,43614,22414,01113,74514,40314,11314,04012,96913,70113,52113,46713,38514,03613,919
  Goodwill0.2%51,57251,47651,37579549,89150,21149,20849,48949,86749,79149,55659,90258,44958,50248,18158,66553,35253,48742,92755,61455,836
Liabilities28.1%120,87594,381101,288102,459107,821101,155104,013103,22199,60589,95390,756113,487113,370100,998104,148105,05196,27496,26395,66496,17494,856
  Current Liabilities-5.2%34,64736,56242,13844,31447,41039,26842,67141,80335,66426,65225,92034,15432,72333,89037,30436,97432,03029,42331,85829,01332,156
    LT Debt, Current-0.1%3,5653,5672,5602,5661,2762601,6362,6633,6873,6762,0022,1491,4813371,4622,4312,1394,4714,7764,2554,262
    LT Debt, Non Current93.5%61,35631,70432,88432,62934,29435,65636,00036,25035,35435,34737,13349,78550,52936,28135,95536,04436,16835,73332,90933,65228,935
Shareholder's Equity-2.2%99,019101,23695,66192,63187,46982,68577,46275,96770,31568,86563,47365,50364,57065,34163,44765,39659,92459,15863,75871,66470,124
  Retained Earnings-1.8%128,796131,102125,656122,967116,608111,193103,394102,25296,34695,15890,392100,284100,203101,00097,670100,11394,44093,38889,57491,99589,860
  Additional Paid-In Capital0.2%92,32992,15391,80291,35991,18390,84490,59189,97389,33689,00288,67488,16187,88687,68087,42887,09986,96386,63586,25385,82884,898
Accumulated Depreciation0.3%15,55415,51415,17414,93114,96915,35815,07415,40315,32815,10514,81216,63616,88916,92916,78916,72816,38916,15816,59117,07816,844
Shares Outstanding0.2%5,6465,634-5,6075,5935,617-5,6095,5985,584-5,5575,5545,545-5,5455,5625,635-5,8755,866
Minority Interest3.0%274266256259261261262275273245235236228312303293357352351346346
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-39.2%14,56023,93829,26726,59931,45434,58332,58032,29123,55215,80814,40312,54714,96714,02312,58813,55714,30615,54215,82718,17817,808
  Share Based Compensation-15.6%7528918721,0041,1621,0961,182973904870755707547559687689928926923927831
Cashflow From Investing-108.7%-27,207-13,035-15,783-13,959-23,408-20,232-22,546-11,630-1,073-5,947-4,271-15,434-22,675-11,566-3,945-1,8761,9802,4084,525530423
Cashflow From Financing223.6%13,627-11,027-14,834-13,170-8,510-13,587-9,816-20,252-21,972-10,256-9,6491,6987,792-2,218-8,485-12,452-17,131-18,188-20,441-17,777-18,082
  Buy Backs---2,0002,0002,0002,000--------8,86513,89515,00015,00012,1987,1686,063

PFE Income Statement

2023-07-02
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jul. 02, 2023
Jul. 03, 2022
Jul. 02, 2023
Jul. 03, 2022
Income Statement [Abstract]    
Revenues$ 12,734$ 27,742$ 31,015$ 53,402
Costs and expenses:    
Cost of sales[1]3,2378,6488,12218,632
Selling, informational and administrative expenses[1]3,4973,0486,9145,642
Research and development expenses[1]2,6482,8155,1535,116
Acquired in-process research and development expenses33155356
Amortization of intangible assets1,1848222,2871,657
Restructuring charges and certain acquisition-related costs214189222381
Other (income)/deductions––net(347)772(277)1,122
Income from continuing operations before provision/(benefit) for taxes on income[2]2,26911,4478,53920,497
Provision/(benefit) for taxes on income(71)1,5706442,742
Income from continuing operations2,3409,8777,89517,756
Discontinued operations––net of tax(2)34(1)26
Net income before allocation to noncontrolling interests2,3389,9117,89417,781
Less: Net income attributable to noncontrolling interests1162412
Net income attributable to Pfizer Inc. common shareholders$ 2,327$ 9,906$ 7,870$ 17,769
Earnings per common share––basic:    
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)$ 0.41$ 1.76$ 1.40$ 3.17
Discontinued operations––net of tax (in dollars per share)00.0100
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)0.411.771.403.17
Earnings per common share––diluted:    
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)0.411.731.383.09
Discontinued operations––net of tax (in dollars per share)00.0100
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)$ 0.41$ 1.73$ 1.38$ 3.10
Weighted-average shares––basic5,6465,5935,6405,605
Weighted-average shares––diluted5,7135,7125,7205,735
[1]Exclusive of amortization of intangible assets.
[2]Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $91 million in the second quarter of 2023 and $69 million in the second quarter of 2022, and $183 million in the first six months of 2023 and $125 million in the first six months of 2022. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $58 million of costs in the second quarter of 2022 and $105 million in the first six months of 2022 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation.

PFE Balance Sheet

2023-07-02
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Jul. 02, 2023
Dec. 31, 2022
Assets  
Cash and cash equivalents$ 2,632$ 416
Short-term investments42,15322,316
Trade accounts receivable, less allowance for doubtful accounts: 2023—$471; 2022—$44910,23110,952
Inventories[1]10,3108,981
Current tax assets3,1943,577
Other current assets4,8285,017
Total current assets73,34751,259
Equity-method investments11,42211,033
Long-term investments3,6444,036
Property, plant and equipment, less accumulated depreciation: 2023—$15,554; 2022—$15,17417,48816,274
Identifiable intangible assets[2]41,40643,370
Goodwill51,57251,375
Noncurrent deferred tax assets and other noncurrent tax assets8,2616,693
Other noncurrent assets13,02813,163
Total assets220,168197,205
Liabilities and Equity  
Short-term borrowings, including current portion of long-term debt: 2023—$3,565; 2022—$2,5603,9852,945
Trade accounts payable6,0816,809
Dividends payable2,3152,303
Income taxes payable2,9281,587
Accrued compensation and related items1,9723,407
Deferred revenues1,2862,520
Other current liabilities16,07922,568
Total current liabilities34,64742,138
Long-term debt61,35632,884
Pension and postretirement benefit obligations2,1842,250
Noncurrent deferred tax liabilities1,2321,023
Other taxes payable8,0529,812
Other noncurrent liabilities13,40313,180
Total liabilities120,875101,288
Commitments and Contingencies
Common stock478476
Additional paid-in capital92,32991,802
Treasury stock(114,482)(113,969)
Retained earnings128,796125,656
Accumulated other comprehensive loss(8,102)(8,304)
Total Pfizer Inc. shareholders’ equity99,01995,661
Equity attributable to noncontrolling interests274256
Total equity99,29395,916
Total liabilities and equity$ 220,168$ 197,205
[1]The increase from December 31, 2022 reflects higher inventory levels for Paxlovid and, to a lesser extent, increases for certain products due to supply recovery and inventory build, partially offset by decreases due to net market demand.
[2]The decrease is primarily due to amortization expense of $2.3 billion and impairments of $248 million (see Note 4), partially offset by additions of $681 million mostly related to milestone payments for the approvals in the U.S. for Zavzpret nasal spray and Ngenla.
Albert Bourla
65535
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.